<DOC>
	<DOCNO>NCT02200991</DOCNO>
	<brief_summary>Primary Objective : To demonstrate significant reduction postprandial plasma glucose ( ΔAUC0:30-4:30h ) standardize breakfast baseline Day 29 . Secondary Objectives : To demonstrate : - Changes baseline Day 29 maximum postprandial plasma glucose excursion , C-peptide glucagon level standardize breakfast - Delaying gastric emptying ( 13C-acetic acid breath test ) - Safety tolerability</brief_summary>
	<brief_title>Effect Lixisenatide Postprandial Plasma Glucose Compared Sitagliptin Combination With Insulin Glargine</brief_title>
	<detailed_description>The duration per patient could minimum 38 47 day depend screen visit post-treatment observation allowance . 13C-acetic acid breath test conduct investigational site implement ( 40 patient ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Inclusion criterion : Type 2 diabetes mellitus , treat Lantus±SU ; ≥5year diagnosis Aged 2075 year Hemoglobin A1C ≥7.0 % ≤10.0 % Fasting plasma glucose ≤180 mg/dL screen Stable treatment ( ±20 % ) Lantus 3 month prior screen . Sulfonylurea dose stable 3 month prior screen Exclusion criterion : Type 1 diabetes mellitus Pregnancy lactation Hypersensitivity Lixisenatide Severely uncontrolled glycemic situation History unexplained pancreatitis , chronic pancreatitis , pancreatectomy , stomach/gastric surgery inflammatory bowel disease History metabolic acidosis , include diabetic ketoacidosis , within 1 year prior screen History within previous 6 month myocardial infarction , stroke heart failure require hospitalization drug alcohol abuse Uncontrolled/inadequately control hypertension time screening , rest systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 95 mmHg Amylase and/or lipase &gt; 3 time aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) alkaline phosphatase ( ALP ) &gt; 2 time upper limit normal laboratory range Endstage renal disease and/or dialysis clinically relevant history gastrointestinal disease The information intend contain consideration relevant patient 's potential participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>